Table 3. Base case and adjusted costs... | American Society of Hematology

Table 3.

Base case and adjusted costs and outcomes of 3 comparator drugs used to treat patients suspected of having HIT

	Unadjusted		Adjusted
Drugs	Total costs	Total benefits (adverse events averted)	Total costs	Total benefits (adverse events averted)
Fondaparinux	CHF 24 923	0.820	CHF 23 097	0.834
Argatroban	CHF 39 207	0.791	CHF 33 749	0.820
Rivaroxaban	CHF 28 542	0.932	CHF 34 585	0.917

	Unadjusted		Adjusted
Drugs	Total costs	Total benefits (adverse events averted)	Total costs	Total benefits (adverse events averted)
Fondaparinux	CHF 24 923	0.820	CHF 23 097	0.834
Argatroban	CHF 39 207	0.791	CHF 33 749	0.820
Rivaroxaban	CHF 28 542	0.932	CHF 34 585	0.917

	Incremental costs	Incremental benefits	Incremental costs	Incremental benefits
Fondaparinux vs Argatroban	−CHF 14 284	0.029	−CHF 10 652	0.013
Fondaparinux vs Rivaroxaban	−CHF 3 602	−0.112	−CHF 11 488	−0.084
Rivaroxaban vs Argatroban	−CHF 10 682	0.141	CHF 835	0.097

	Incremental costs	Incremental benefits	Incremental costs	Incremental benefits
Fondaparinux vs Argatroban	−CHF 14 284	0.029	−CHF 10 652	0.013
Fondaparinux vs Rivaroxaban	−CHF 3 602	−0.112	−CHF 11 488	−0.084
Rivaroxaban vs Argatroban	−CHF 10 682	0.141	CHF 835	0.097